Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: Results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS)

Clinical and Experimental Hypertension

Volumn 37, Issue 2, 2015, Pages 116-121

  Silva, Pedro M ^a   Cardoso, Salvador M ^b   Ferreira, Antonio M ^c  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c HOSPITAL DE SANTA CRUZ   (Portugal)

Author keywords

Cardiovascular disease; Dyslipidemia; HMG CoA; Hypertension; Simvastatin; Statins

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; LIPID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PORTUGUESE (CITIZEN); PREVALENCE; BLOOD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DYSLIPIDEMIAS; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PORTUGAL; PRIMARY PREVENTION; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY PREVENTION;

AGED; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PORTUGAL; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION;

EID: 84924812227     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2014.913605     Document Type: Article

References (41)

1. Murray CJ, Vos T, Lozano R, Naghavi M. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245.
3. deGoma EM, Knowles JW, Angeli F, et al. The evolution and refinement of traditional risk factors for cardiovascular disease. Cardiol Rev 2012; 20: 118-29.
4. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-13.
5. Esquirol Y, Perret B, Ruidavets JB, et al. Shift work and cardiovascular risk factors: new knowledge from the past decade. Arch Cardiovasc Dis 2011;104:636-68.
6. Poulter N. Global risk of cardiovascular disease. Heart 2003;89: ii2-7.
7. ATPIII Final Report. II Rationale for intervention. Circulation 2002;106:3163-223.
8. Onat A, Hergenç G, Sari I, et al. Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study. Am J Hypertens 2005;18:409-16.
9. Chamberlain DA, Tunstall-Pedoe H. Coronary artery disease: a European perspective. Eur Heart J 2002;13:54-8.
10. Ezzati M, Lopez AD, Rogers A, et al. Selected major risk factors and global and region burden of disease. Lancet 2002;360:1347-60.
11. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
12. MacDonald TM, Morant SV. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol 2008;65:775-86.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
14. Mihaylova B, Emberson J, Blackwell L, et al. The effect of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
15. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362: 1527-35.
16. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
17. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.
18. Mansia G, De Backer G, Dominiczak A, et al. ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16:135-232.
19. Bozentowicz-Wikarek M, Kocełak P, Smertka M, et al. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis-guidelines vs. reality. Pharmacol Rep 2012;64:377-85.
20. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373: 929-40.
21. Dutro MP, Gerthoffer TD, Peterson ED, et al. Treatment of hypertension and dyslipidemia or their combination among US managed-care patients. J Clin Hypertens (Greenwich) 2007;9: 684-91.
22. Petrella RJ, Merikle E. A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in Southwestern Ontario, Canada. Clin Ther 2008;30:1145-54.
23. Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011;28:1343-51.
24. Gitt AK, Drexel H, Feely J, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012;19:221-30.
25. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28: 2375-414.
26. Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109: 433-8.
27. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.
28. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
29. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376: 112-23.
30. Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
31. Olives C, Myerson R, Mokdad AH, et al. Prevalence, awareness, treatment, and control of hypertension in United States counties, 2001-2009. PLoS One 2013;8:e60308.
32. Grassi G, Cifkova R, Laurent S, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J 2011;32:218-25.
33. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818.
34. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. [Epub ahead of print]. doi: 10.1161/01.cir.0000437738.63853.7a.
35. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
36. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
37. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
38. Margolis KL, Davis BR, Baimbridge C, et al. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) 2013;15:542-54.
39. Bloch MJ. What does ALLHAT tell us about dyslipidemia from the hypertension specialist perspective? J Clin Hypertens (Greenwich) 2013;15:530-1.
40. Kobayashi M, Chisaki I, Narumi K, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci 2008;82:969-75.
41. Niska R, Han B. Statins for secondary cardiovascular disease prevention for older primary care patients. J Natl Med Assoc 2009; 101:705-10.